IRIX 8-K
Iridex Corp (IRIX)
|
UNITED STATES Washington, D.C. 20549 |
||||||
|
FORM CURRENT REPORT |
||||||
|
PURSUANT TO SECTION 13 OR 15(d) OF THE |
||||||
|
|
|
|
||||
|
(Date of Report (date of earliest event reported) |
||||||
|
|
||||||
|
(Exact name of registrant as specified in its charter) |
||||||
|
|
|
|
||||
|
(State or other jurisdiction of |
(Commission File Number) |
(I.R.S. Employer |
||||
|
|
||||||
|
(Address of principal executive offices, including zip code) |
||||||
|
|
( |
|
||||
|
|
(Registrant’s telephone number, including area code) |
|
||||
|
|
||||||
|
(Former name or former address, if changed since last report) |
||||||
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
||||||
|
Emerging growth company |
||||||
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
||||||
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Class |
|
Trading Symbol |
|
Name of Exchange on Which Registered |
|
|
|
|
|
|
Item 2.02.Results of Operations and Financial Condition.
On May 12, 2022, IRIDEX Corporation issued a press release discussing its financial results for its first fiscal quarter of fiscal year 2022, which ended on April 2, 2022. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
|
|
|
|
(d) |
Exhibits |
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
|
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
IRIDEX CORPORATION |
|
|
|
|
|
|
|
By: |
|
/s/David I. Bruce |
|
|
|
|
David I. Bruce |
|
|
|
|
President and Chief Executive Officer |
|
|
|
|
|
|
Date: May 12, 2022 |
|
|
|
-3-
Exhibit 99.1
Iridex Announces First Quarter 2022 Financial Results
Achieved Record First Quarter Revenue
MOUNTAIN VIEW, Calif., May 12, 2022 -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 2, 2022.
First Quarter 2022 Highlights
|
|
• |
Record first quarter revenue of $13.4 million, an increase of 12% from the prior year period |
|
|
• |
Cyclo G6® product family revenue of $3.5 million, an increase of 6% year-over-year |
|
|
o |
14,700 Cyclo G6 probes sold, an 8% increase year-over-year |
|
|
o |
56 Cyclo G6 Glaucoma Laser Systems sold, compared to 64 in the prior year |
|
|
• |
Retina product revenue increased 10% year-over-year to $7.3 million |
|
|
o |
PASCAL® products acquired from Topcon contributed 29% of retina revenue |
|
|
• |
Net Cash use of $3.2 million resulting in cash balance on April 2, 2022 of $20.6 million |
“Record first quarter results demonstrate the continued traction our strengthened U.S. and international commercial network are achieving in the global ophthalmology market. We continue to make steady progress building physician adoption of our non-incisional approach to treating glaucoma and retinal disease,” said David Bruce, President and CEO of Iridex. “Volatility in procedure volumes from COVID surges began to subside mid-quarter, leading to a stronger second half of the quarter as many of our customers’ practices returned to more normal activity.”
“We also mitigated our exposure to potential supply chain risks by increasing inventory of long-lead parts and making pre-payments to suppliers to ensure delivery commitments in the quarters to come, resulting in increases of inventory and prepaid expenses by about $2 million.”
“We plan to continue our focused investment in clinical evidence, KOL support, and expanding physician-to-physician messaging on the benefits of our MicroPulse TLT treatment to drive worldwide adoption and remain confident in our plan to deliver strong results throughout 2022,” concluded Bruce.
First Quarter 2022 Financial Results
Revenue for the three months ended April 2, 2022 increased 12% to $13.4 million from $12.0 million during the same period of the prior year. The increase in revenue was driven by higher Glaucoma product revenue and continued strength of the Retina product line in both domestic and international markets, including full quarter sales of the PASCAL product line acquired from Topcon.
Total product revenue from the Cyclo G6 glaucoma product family was $3.5 million, up 6% compared to the first quarter of 2021. Retina product revenue improved in the first quarter to $7.3 million, an increase of 10% compared to the prior year period. Other revenue, which includes royalties, services, and other legacy products, increased 31% to $2.5 million in the first quarter of 2022 compared to the same period in 2021. The substantial Other revenue increase resulted from inclusion of PASCAL service revenue and amortized revenue recognition from the sale of distribution rights to Topcon.
Gross profit for the first quarter of 2022 increased 21% to $6.0 million, or a 44.6% gross margin, compared to $4.9 million, and a 41.3% gross margin, in the same period of the prior year. Higher gross margin was driven by the longer-term strategic focus to increase higher margin probes within the product mix, continuing pricing discipline and inclusion of recognized revenue from the sale of distribution rights to Topcon.
Operating expenses for the first quarter of 2022 increased 22% to $8.3 million compared to $6.8 million in the same period of the prior year. The increase is the result of the planned expansion of our sales and marketing programs and in continued R&D investment in PASCAL and other new product development initiatives.
Net loss for the first quarter of 2022 was $2.4 million, or $0.15 per share compared to a net loss of $2.0 million or $0.14 per share in the same period of the prior year.
Guidance for Full Year 2022
Iridex reiterates its guidance for Cyclo G6 probe sales of 67,000 to 70,000 representing 15% to 20% growth and Cyclo G6 systems installed base to expand by 225 to 250 in 2022. Total revenue for the full year is expected to be $57 million to $59 million.
Webcast and Conference Call Information
Iridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 3366993. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com.
About Iridex
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning clinical and commercial momentum, demand for and utilization of the Company's products, financial guidance and results and expected sales volumes. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the fiscal year ended January 1, 2022.
Investor Relations Contact
Hunter Cabi
IRIDEX Corporation
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(unaudited)
|
|
|
Three Months Ended |
|
|||||
|
|
|
April 2, |
|
|
April 3, |
|
||
|
|
|
2022 |
|
|
2021 |
|
||
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
$ |
13,387 |
|
|
$ |
11,959 |
|
|
Cost of revenues |
|
|
7,410 |
|
|
|
7,020 |
|
|
Gross profit |
|
|
5,977 |
|
|
|
4,939 |
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
Research and development |
|
|
2,116 |
|
|
|
1,165 |
|
|
Sales and marketing |
|
|
4,300 |
|
|
|
2,982 |
|
|
General and administrative |
|
|
1,838 |
|
|
|
2,633 |
|
|
Total operating expenses |
|
|
8,254 |
|
|
|
6,780 |
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(2,277 |
) |
|
|
(1,841 |
) |
|
Other expense, net |
|
|
(94 |
) |
|
|
(161 |
) |
|
Loss from operations before provision for income taxes |
|
|
(2,371 |
) |
|
|
(2,002 |
) |
|
Provision for income taxes |
|
|
20 |
|
|
|
8 |
|
|
Net loss |
|
$ |
(2,391 |
) |
|
$ |
(2,010 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net loss per share: |
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.15 |
) |
|
$ |
(0.14 |
) |
|
Diluted |
|
$ |
(0.15 |
) |
|
$ |
(0.14 |
) |
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net loss per share |
|
|
|
|
|
|
|
|
|
Basic |
|
|
15,881 |
|
|
|
14,346 |
|
|
Diluted |
|
|
15,881 |
|
|
|
14,346 |
|
IRIDEX Corporation
Condensed Consolidated Balance Sheets
(In thousands and unaudited)
|
|
|
April 2, |
|
|
January 1, |
|
||
|
|
|
2022 |
|
|
2022 |
|
||
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
20,621 |
|
|
$ |
23,852 |
|
|
Accounts receivable, net |
|
|
10,451 |
|
|
|
9,716 |
|
|
Inventories |
|
|
9,091 |
|
|
|
7,614 |
|
|
Prepaid expenses and other current assets |
|
|
1,766 |
|
|
|
1,071 |
|
|
Total current assets |
|
|
41,929 |
|
|
|
42,253 |
|
|
Property and equipment, net |
|
|
363 |
|
|
|
428 |
|
|
Intangible assets, net |
|
|
2,157 |
|
|
|
2,205 |
|
|
Goodwill |
|
|
965 |
|
|
|
965 |
|
|
Operating lease right-of-use assets, net |
|
|
2,332 |
|
|
|
2,565 |
|
|
Other long-term assets |
|
|
278 |
|
|
|
271 |
|
|
Total assets |
|
$ |
48,024 |
|
|
$ |
48,687 |
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
4,353 |
|
|
$ |
3,399 |
|
|
Accrued compensation |
|
|
2,325 |
|
|
|
3,192 |
|
|
Accrued expenses |
|
|
1,646 |
|
|
|
1,575 |
|
|
Other current expenses |
|
|
853 |
|
|
|
1,098 |
|
|
Accrued warranty |
|
|
117 |
|
|
|
100 |
|
|
Deferred revenue |
|
|
2,356 |
|
|
|
2,355 |
|
|
Operating lease liabilities |
|
|
938 |
|
|
|
927 |
|
|
Total current liabilities |
|
|
12,588 |
|
|
|
12,646 |
|
|
|
|
|
|
|
|
|
|
|
|
Long-term liabilities: |
|
|
|
|
|
|
|
|
|
Accrued warranty |
|
|
76 |
|
|
|
58 |
|
|
Deferred revenue |
|
|
12,531 |
|
|
|
10,930 |
|
|
Operating lease liabilities |
|
|
1,479 |
|
|
|
1,729 |
|
|
Other long-term liabilities |
|
|
24 |
|
|
|
25 |
|
|
Total liabilities |
|
|
26,698 |
|
|
|
25,388 |
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
|
|
|
Common stock |
|
|
168 |
|
|
|
168 |
|
|
Additional paid-in capital |
|
|
85,645 |
|
|
|
85,255 |
|
|
Accumulated other comprehensive income (loss) |
|
|
73 |
|
|
|
45 |
|
|
Accumulated deficit |
|
|
(64,560 |
) |
|
|
(62,169 |
) |
|
Total stockholders' equity |
|
|
21,326 |
|
|
|
23,299 |
|
|
Total liabilities and stockholders' equity |
|
$ |
48,024 |
|
|
$ |
48,687 |
|